| Dear Voornaam
Join us at the Cancer Research Horizons Innovation Summit on 21 November to network with fellow innovative researchers and industry partners, discover how to create your own startup and receive advice and tips on the entrepreneurial journey.
This free event will take place at the Royal Society of Medicine in London and is an opportunity for you to hear from researchers who have successfully translated their findings into effective tools, tests and treatments for cancer patients. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
CANCER RESEARCH HORIZONS TAKES CENTRE STAGE AT ELRIG DRUG DISCOVERY 2023 Our innovation arm, Cancer Research Horizons, will be hosting the Transforming Cancer Drug Discovery track and spotlighting leading experts in oncology at the ELRIG Drug Discovery conference 2023.
This free-to-attend conference promises two days of talks that delve into a wide range of themes from ‘omics, personalised medicine to chemistry.
Join on 18–19 October in Liverpool to connect with like-minded professionals, gain valuable industry insights and help drive forward the discussions that bring new therapies from the lab to the patient. |
|
|---|
|
|---|
|
|
NEW IN MOLECULAR CELL: THE MECHANISMS BEHIND AGEING IN HEMATOPOIETIC STEM CELLS What causes ageing?
Meng Wang, Ketan J Patel and colleagues from the University of Cambridge investigated the mechanisms that underpin premature ageing of hematopoietic stem cells.
Their work suggests, at least in blood, that the changes associated with ageing can arise from a triggered cellular response rather than attrition-related decline.
To recapitulate the changes observed in blood ageing, the authors looked at young mice and found that genotoxic aldehydes cause accelerated ageing. Aged cells also showed increased activation of p53 response, and interestingly, ageing was prevented when p53 was deleted in these stem cells.
From these findings, the authors developed the Haem p53Score, which can detect increased p53 activity in mouse and human cells. Using this, they detected high p53 activity in a subset of leukaemia, which associates with worse survival. |
|
|---|
|
|---|
|
|
IAIN FOULKES REFLECTS ON THE ROLE OF INNOVATION IN R&D “If we’re not careful the UK will lose its position as a global leader in oncology trials,” says Iain Foulkes, our Executive Director of R&I and CEO of Cancer Research Horizons.
On the heels of a busy international conference month, Iain reflects on some of the themes from ASCO and stresses the need to speed up our ability to translate science, innovation and diagnostics to stay at the forefront of research and development. |
|
|---|
| FROM BASIC BIOLOGY TO TRANSFORMATIVE THERAPIES IN LUNG CANCER Colin Lindsay, Clinical Senior Lecturer at The Christie and the University of Manchester, is the latest voice in the Manchester Cancer Research podcast.
Colin shares insights from his research in lung cancer, how he came to study KRAS and his work on sotorasib, which has now been approved by the FDA and NICE.
Tune in to hear how his research is driving forward knowledge on the vulnerabilities of the RAS gene family. |
|
|---|
|
|---|
|
|
DETERMINE JOINS EUROPEAN COLLABORATION Our Centre for Drug Development has joined the PRIME-ROSE project to further the progress of the DETERMINE trial, a multi-drug, precision medicine platform trial for adults and children with rare cancers.
The PRIME-ROSE project is a Europe-wide consortium of 24 partners, created to improve patient access to precision cancer medicine. This international collaboration will enable data aggregation and analysis from multiple trials and allow significantly more data for rare cancers to be collected. |
|
|---|
|
|---|
|
|
CHILDREN’S AND YOUNG PEOPLE’S PRECISION MEDICINE WEBINAR Are you working in children’s and young people’s cancer, or could you apply your research to this area?
Our next webinar focused on precision medicine is bringing together a panel of international experts to share how data, tools and techniques could help better treat and diagnose children and young people affected by cancer.
Join the webinar on 5 July at 4 PM. |
|
|---|
| A PRELIMINARY PREDICTIVE MODEL FOR DCIS PROGRESSION USING MICROCALCIFICATION CRYSTALLOGRAPHY Sarah Gosling and colleagues investigated crystallographic and chemical features of DCIS microcalcifications as potential markers of DCIS recurrence as part of the PRECISION team’s Cancer Grand Challenge to distinguish between lethal cancers that need treating, and non-lethal cancers that don’t.
Using X-ray diffraction and electron microscopy, the authors compared breast tissue samples from people with DCIS either with no known recurrence within 5 years or with recurrence as ipsilateral invasive breast cancer. The findings were recently published in Scientific Reports.
They found significant differences between the microcalcifications of the two groups and used some of the crystallographic and elemental features to develop a preliminary predictive model for DCIS to invasive cancer progression.
Their results provide insights into the different microenvironments of DCIS tissue and how these impact microcalcification formation. |
|
|---|
|
|---|
|
|
THAT CANCER CONVERSATION ON LGBTQ+ CANCER CARE In the latest episode of our podcast series That Cancer Conversation, Alison Berner (Barts Cancer Institute) and Stewart O’Callaghan (Live Through This) talk about the inequalities in cancer care in the LGBTQ+ community and what needs to change to reduce them.
Alison explores the reasons behind the lack of data on cancer in the LGBTQ+ population, how researchers often work in silos and can be bogged down by the ‘middle author syndrome’ and calls for more data to drive interest and funding in the field.
Hear more from Alison and Stewart about the small changes that can be made to reduce barriers, why healthcare professionals are calling for more specific education and how patients, professionals and policymakers can work together to create a more inclusive space. |
|
|---|
|
|---|
|
|
| | | Online 4:00 PM 05 July 2023 |
|
|---|
|
|---|
| | | London, UK 11 September 2023 |
|
|---|
|
|---|
| | | Online 4:00 PM 27 September 2023 |
|
|---|
|
|---|
| | | Paris, France 04 October 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
| | | Liverpool, UK 18 October 2023 |
|
|---|
|
|---|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
